查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951951

干细胞製造市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、最终用户、製程、阶段

Stem Cell Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage
出版日期: | 出版商: Global Insight Services | 英文 303 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计干细胞生产市场规模将从2024年的139亿美元成长到2034年的342亿美元，复合年增长率约为10.3%。干细胞生产市场涵盖用于治疗、研究和药物开发的干细胞的生产和扩增。该市场包括先进的生物製程技术、可扩展的培养系统以及确保细胞活力和效力的品管措施。对再生医学和个人化疗法的需求不断增长，推动了市场发展，而自动化和生物反应器设计的创新则提高了生产效率和扩充性。

干细胞生产市场正经历强劲成长，这主要得益于再生医学的进步和治疗应用的不断拓展。在细胞治疗生产领域，这一增长尤为显着，主要受异体和自体干细胞疗法需求的推动。其中，异体干细胞疗法细分市场成长最为迅猛，这主要归功于其扩充性和大规模生产的潜力；其次是提供个人化治疗方案、改善患者预后的异体干细胞疗法。生物製剂生产设备领域也表现强劲，生物反应器和细胞培养系统在高效干细胞生产中发挥关键作用。第二大成长领域－耗材细分市场（包括培养基和试剂）预计将显着成长，这主要得益于干细胞培养对高品质原料的持续需求。对自动化和流程标准化的高度重视正在推动创新，确保产品品质的稳定性并降低生产成本。这些趋势为投资和策略合作提供了有利机会。

市场区隔
类型 成体干细胞、胚胎干细胞、诱导性多功能干细胞
产品 细胞株、设备、耗材、培养基及试剂
服务 细胞库、细胞鑑定、细胞分化、细胞扩增、冷冻保存、品管
科技 3D细胞培养、生物反应器、细胞分离、细胞分选、冷冻保存
应用领域 再生医学、药物发现、毒性测试、组织工程、临床研究
最终用户 生技公司、製药公司、研究机构、医院、学术机构
过程 上游工程、下游製程、细胞增殖、细胞收穫
步 研究与开发、临床试验和商业化生产

干细胞製造市场正面临不断变化的格局，其特点是策略性定价和创新产品不断涌现。各公司正利用先进技术提高生产效率，并优化定价策略以保持竞争力。专注于治疗应用和再生医学的新型干细胞产品正在推动市场动态。这一趋势凸显了对个人化医疗日益增长的需求，增强了市场的吸引力，并推动了强劲的成长前景。干细胞製造领域的竞争异常激烈，主要企业正寻求透过技术创新和策略联盟来巩固主导。法规结构，尤其是在北美和欧洲，在塑造市场标准和影响竞​​争格局方面发挥关键作用。这些法规确保了产品的安全性和有效性，并促进了创新和合规性。该市场的特点是高度重视研发活动，并投入大量资金来改善生产流程和扩展产品系列。这种竞争格局表明，在监管影响和技术进步的驱动下，该市场已做好持续成长的准备。

主要趋势和驱动因素：

干细胞生产市场正经历强劲成长，这主要得益于再生医学和个人化疗法的进步。关键趋势包括将自动化和人工智慧融入生产流程，从而提高精度和效率。细胞疗法因其治疗慢性疾病的潜力而日益受到关注，这是推动市场发展的关键因素。此外，探索干细胞应用的临床试验不断扩展，也加速了市场的发展动能。监管机构的支持和政府对干细胞研究的资助对于推动市场扩张至关重要。这种支持促进了创新，并支持了新型治疗方法的开发。学术机构和产业参与者之间日益密切的合作正在刺激研发活动，并加速干细胞产品的商业化进程。此外，对生产流程中品管和标准化的日益重视，确保了产品的安全性和有效性，进一步增强了市场信心。新兴市场医疗基础设施的不断改进和人们对干细胞疗法的认识不断提高，为市场带来了大量机会。投资于策略合作和技术创新的公司将更有利于获得市场份额。随着产业的不断发展，专注于开发扩充性、经济高效的生产解决方案对于满足不断增长的需求至关重要。干细胞製造市场预计将在创新和治疗应用不断扩展的推动下持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 成体干细胞
    • 胚胎干细胞
    • 诱导性多功能干细胞
  • 市场规模及预测：依产品划分
    • 细胞株
    • 装置
    • 消耗品
    • 培养基
    • 试剂
  • 市场规模及预测：依服务划分
    • 细胞库
    • 细胞表征
    • 细胞分化
    • 细胞增殖
    • 冷冻保存
    • 品管
  • 市场规模及预测：依技术划分
    • 3D细胞培养
    • 生物反应器
    • 细胞分离
    • 细胞分级分离
    • 冷冻保存
  • 市场规模及预测：依应用领域划分
    • 再生医学
    • 药物发现
    • 毒理学研究
    • 组织工程
    • 临床研究
  • 市场规模及预测：依最终用户划分
    • 生技公司
    • 製药公司
    • 研究所
    • 医院
    • 学术机构
  • 市场规模及预测：依製程划分
    • 上游工程
    • 下游工艺
    • 细胞增殖
    • 细胞收集
  • 市场规模及预测：依阶段划分
    • 研究与开发
    • 临床试验
    • 商业生产

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Lonza
  • Thermo Fisher Scientific
  • STEMCELL Technologies
  • Cell Genix
  • Cytiva
  • Promo Cell
  • Bio-Techne
  • Takara Bio
  • Miltenyi Biotec
  • Pluristem Therapeutics
  • Fujifilm Cellular Dynamics
  • Astellas Institute for Regenerative Medicine
  • Re Neuron Group
  • Brain Storm Cell Therapeutics
  • Mesoblast
  • Gamida Cell
  • Organogenesis
  • Vericel Corporation
  • Athersys
  • Cellectis

第九章：关于我们

简介目录
Product Code: GIS20577

Stem Cell Manufacturing Market is anticipated to expand from $13.9 billion in 2024 to $34.2 billion by 2034, growing at a CAGR of approximately 10.3%. The Stem Cell Manufacturing Market encompasses the production and expansion of stem cells for therapeutic applications, research, and drug development. This market includes advanced bioprocessing technologies, scalable culture systems, and quality control measures to ensure cell viability and potency. Rising demand for regenerative medicine and personalized therapies is propelling growth, with innovations in automation and bioreactor design enhancing production efficiency and scalability.

The Stem Cell Manufacturing Market is experiencing robust growth, fueled by advancements in regenerative medicine and increasing therapeutic applications. The cell therapy manufacturing segment stands out, driven by the demand for allogeneic and autologous stem cell therapies. Within this segment, the allogeneic therapies sub-segment is the top performer, attributed to its scalability and potential for mass production. Autologous therapies follow, offering personalized treatment options that enhance patient outcomes. The biologics manufacturing equipment segment also exhibits strong performance, with bioreactors and cell culture systems playing pivotal roles in efficient stem cell production. As the second highest-performing segment, the consumables sub-segment, including media and reagents, is expected to grow significantly due to the continuous need for high-quality inputs in stem cell cultures. The emphasis on automation and process standardization is driving innovation, ensuring consistent product quality and reducing manufacturing costs. These trends indicate lucrative opportunities for investment and strategic partnerships.

Market Segmentation
TypeAdult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells
ProductCell Lines, Instruments, Consumables, Culture Media, Reagents
ServicesCell Banking, Cell Characterization, Cell Differentiation, Cell Expansion, Cryopreservation, Quality Control
Technology3D Cell Culture, Bioreactors, Cell Isolation, Cell Sorting, Cryopreservation
ApplicationRegenerative Medicine, Drug Discovery, Toxicology Studies, Tissue Engineering, Clinical Research
End UserBiotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals, Academic Institutions
ProcessUpstream Processing, Downstream Processing, Cell Expansion, Cell Harvesting
StageResearch and Development, Clinical Trials, Commercial Production

The Stem Cell Manufacturing Market is witnessing an evolving landscape marked by strategic pricing and innovative product launches. Companies are leveraging advanced technologies to enhance production efficiency, thereby optimizing pricing strategies to remain competitive. The introduction of novel stem cell products is driving market dynamics, with a focus on therapeutic applications and regenerative medicine. This trend underscores the growing demand for personalized medicine, enhancing market attractiveness and fostering robust growth prospects. Competition within the stem cell manufacturing sector is intense, with key players striving for dominance through technological advancements and strategic partnerships. Regulatory frameworks, particularly in North America and Europe, play a pivotal role in shaping market standards and influencing the competitive landscape. These regulations ensure product safety and efficacy, driving innovation and compliance. The market is characterized by a strong focus on R&D activities, with substantial investments directed towards improving manufacturing processes and expanding product portfolios. This competitive benchmarking reveals a market poised for sustained growth, driven by regulatory influences and technological progress.

Geographical Overview:

The stem cell manufacturing market is witnessing robust growth across diverse regions, each exhibiting unique trends. North America dominates, propelled by cutting-edge research and substantial funding in regenerative medicine. The region's advanced healthcare infrastructure and strong regulatory support bolster market expansion. Europe follows, with significant investments in stem cell research and a growing focus on personalized medicine. The region's commitment to innovative healthcare solutions enhances its market position. In Asia Pacific, rapid technological advancements and increasing government support drive market growth. Countries like China and Japan are emerging as key players, investing heavily in stem cell research and manufacturing capabilities. Latin America and the Middle East & Africa present burgeoning opportunities. In Latin America, rising healthcare investments and growing awareness of stem cell therapies contribute to market expansion. The Middle East & Africa are recognizing the potential of stem cell technologies in addressing prevalent health challenges, thereby fostering market growth and innovation.

Global tariffs and geopolitical tensions are significantly influencing the Stem Cell Manufacturing Market. Japan and South Korea are enhancing domestic capabilities to mitigate reliance on foreign imports, particularly from the US and China. China's strategic pivot towards self-reliance is evident in its substantial investments in biotech infrastructure, while Taiwan leverages its expertise in precision manufacturing to maintain a competitive edge. The parent market is experiencing robust growth, driven by advancements in regenerative medicine and increasing demand for personalized therapies. By 2035, the market is poised for substantial expansion, underpinned by collaborative regional partnerships and innovation. Middle East conflicts exert pressure on global supply chains, potentially elevating energy costs, which could indirectly affect manufacturing expenses and timelines across these Asian markets.

Key Trends and Drivers:

The Stem Cell Manufacturing Market is experiencing robust growth, propelled by advancements in regenerative medicine and personalized therapies. Key trends include the integration of automation and artificial intelligence in manufacturing processes, enhancing precision and efficiency. The increasing demand for cell-based therapies, driven by their potential to treat chronic diseases, is a significant market driver. Moreover, the expansion of clinical trials exploring stem cell applications is fueling market momentum. Regulatory support and government funding for stem cell research are pivotal in driving market expansion. This support is encouraging innovation and facilitating the development of novel therapies. The rise of collaborations between academic institutions and industry players is fostering research and development activities, catalyzing the commercialization of stem cell products. Additionally, the growing focus on quality control and standardization in manufacturing processes is ensuring product safety and efficacy, further boosting market confidence. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of stem cell therapies is increasing. Companies that invest in strategic partnerships and technological advancements are well-positioned to capture market share. As the industry evolves, the focus on developing scalable and cost-effective manufacturing solutions will be crucial to meet the rising demand. The Stem Cell Manufacturing Market is poised for sustained growth, driven by innovation and expanding therapeutic applications.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Adult Stem Cells
    • 4.1.2 Embryonic Stem Cells
    • 4.1.3 Induced Pluripotent Stem Cells
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Instruments
    • 4.2.3 Consumables
    • 4.2.4 Culture Media
    • 4.2.5 Reagents
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Banking
    • 4.3.2 Cell Characterization
    • 4.3.3 Cell Differentiation
    • 4.3.4 Cell Expansion
    • 4.3.5 Cryopreservation
    • 4.3.6 Quality Control
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 3D Cell Culture
    • 4.4.2 Bioreactors
    • 4.4.3 Cell Isolation
    • 4.4.4 Cell Sorting
    • 4.4.5 Cryopreservation
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Regenerative Medicine
    • 4.5.2 Drug Discovery
    • 4.5.3 Toxicology Studies
    • 4.5.4 Tissue Engineering
    • 4.5.5 Clinical Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
    • 4.7.3 Cell Expansion
    • 4.7.4 Cell Harvesting
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Research and Development
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercial Production

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Lonza
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 STEMCELL Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cell Genix
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Cytiva
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Promo Cell
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bio- Techne
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Takara Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Miltenyi Biotec
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Pluristem Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Fujifilm Cellular Dynamics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Astellas Institute for Regenerative Medicine
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Re Neuron Group
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Brain Storm Cell Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Mesoblast
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gamida Cell
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Organogenesis
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vericel Corporation
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Athersys
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cellectis
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us